慢性移植物抗宿主病生物学：美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目的一份特别工作组报告。
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.
作者信息
Cooke Kenneth R, Luznik Leo, Sarantopoulos Stefanie, Hakim Frances T, Jagasia Madan, Fowler Daniel H, van den Brink Marcel R M, Hansen John A, Parkman Robertson, Miklos David B, Martin Paul J, Paczesny Sophie, Vogelsang Georgia, Pavletic Steven, Ritz Jerome, Schultz Kirk R, Blazar Bruce R
机构信息
Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland.
Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland.
出版信息
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3.
Abstract
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality and disability in allogeneic hematopoietic cell transplantation recipients and a major obstacle to improving outcomes. The biology of chronic GVHD remains enigmatic, but understanding the underpinnings of the immunologic mechanisms responsible for the initiation and progression of disease is fundamental to developing effective prevention and treatment strategies. The goals of this task force review are as follows: This document is intended as a review of our understanding of chronic GVHD biology and therapies resulting from preclinical studies, and as a platform for developing innovative clinical strategies to prevent and treat chronic GVHD.
摘要
慢性移植物抗宿主病（GVHD）是异基因造血细胞移植受者晚期非复发死亡率和致残率的主要原因，也是改善治疗结果的主要障碍。慢性GVHD的生物学机制仍然不明，但了解引发和推动疾病进展的免疫机制基础对于制定有效的预防和治疗策略至关重要。本特别工作组综述的目标如下：本文旨在回顾我们对慢性GVHD生物学以及临床前研究所得出的治疗方法的理解，并作为制定预防和治疗慢性GVHD的创新临床策略的平台。
相似文献
1
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.慢性移植物抗宿主病生物学：美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目的一份特别工作组报告。
Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. doi: 10.1016/j.bbmt.2016.09.023. Epub 2016 Oct 3.
2
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.慢性移植物抗宿主病治疗反应的评估。美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目：IV。2014年反应标准工作组报告。
Biol Blood Marrow Transplant. 2015 Jun;21(6):984-99. doi: 10.1016/j.bbmt.2015.02.025. Epub 2015 Mar 19.
3
T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.移植物抗宿主病和移植物抗肿瘤中的 T 细胞亚群。
Front Immunol. 2021 Oct 5;12:761448. doi: 10.3389/fimmu.2021.761448. eCollection 2021.
4
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.慢性移植物抗宿主病治疗反应的评估：美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目：IV. 反应标准工作组报告
Biol Blood Marrow Transplant. 2006 Mar;12(3):252-66. doi: 10.1016/j.bbmt.2006.01.008.
5
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识发展项目：III. 2014年生物标志物工作组报告。
Biol Blood Marrow Transplant. 2015 May;21(5):780-92. doi: 10.1016/j.bbmt.2015.01.003. Epub 2015 Jan 30.
6
Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease.单基因免疫性疾病为慢性移植物抗宿主病的发病机制和治疗提供了新视角。
Front Immunol. 2021 Feb 4;11:574569. doi: 10.3389/fimmu.2020.574569. eCollection 2020.
7
New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation.异基因造血干细胞移植后分离移植物抗宿主病和移植物抗肿瘤效应的新方法。
Br J Haematol. 2013 Jan;160(2):133-45. doi: 10.1111/bjh.12115. Epub 2012 Nov 5.
8
Memory T cells: A helpful guard for allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.记忆性T细胞：异基因造血干细胞移植的有益卫士，且不会引发移植物抗宿主病。
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):211-219. doi: 10.1016/j.hemonc.2017.05.006. Epub 2017 Jun 13.
9
Current issues in chronic graft-versus-host disease.慢性移植物抗宿主病的当前问题
Blood. 2014 Jul 17;124(3):374-84. doi: 10.1182/blood-2014-01-514752. Epub 2014 Jun 9.
10
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.美国国立卫生研究院慢性移植物抗宿主病临床试验标准共识开发项目：四、2020 年高度病态形式报告。
Transplant Cell Ther. 2021 Oct;27(10):817-835. doi: 10.1016/j.jtct.2021.06.001. Epub 2021 Jun 10.
引用本文的文献
1
Reduced splenic volume and advanced age predict sepsis in patients with Howell-Jolly bodies: a retrospective cohort study.脾脏体积减小和高龄可预测豪-乔小体患者发生脓毒症：一项回顾性队列研究。
Int J Hematol. 2025 Aug 12. doi: 10.1007/s12185-025-04050-9.
2
Targeting hypoxia-inducible factor 1α in chronic graft-versus-host disease to enhance graft-versus-leukemia responses: implications for nanotherapeutics.靶向慢性移植物抗宿主病中的缺氧诱导因子1α以增强移植物抗白血病反应：对纳米疗法的启示
Front Immunol. 2025 Jul 28;16:1605669. doi: 10.3389/fimmu.2025.1605669. eCollection 2025.
3
Impact of CD34 cell dose on outcomes of haploidentical peripheral blood stem cell transplantation in acute leukemia.CD34细胞剂量对急性白血病单倍体相合外周血干细胞移植结局的影响
Blood Res. 2025 Aug 7;60(1):42. doi: 10.1007/s44313-025-00091-5.
4
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial.接受间充质基质细胞治疗类固醇难治性急性移植物抗宿主病的患者慢性移植物抗宿主病的发病率和死亡率降低：一项随机3期试验的长期随访
Exp Hematol Oncol. 2025 Jul 9;14(1):95. doi: 10.1186/s40164-025-00687-8.
5
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy.美国食品药品监督管理局批准摘要：阿沙替利单抗用于接受过两线全身治疗后患有慢性移植物抗宿主病的体重至少40公斤的成人和儿科患者。
Clin Cancer Res. 2025 Jun 27. doi: 10.1158/1078-0432.CCR-25-0896.
6
Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.通过细胞因子刺激增强运动动员的供体淋巴细胞输注，用于预防和治疗异基因造血细胞移植后的白血病复发。
Front Immunol. 2025 Jun 12;16:1563972. doi: 10.3389/fimmu.2025.1563972. eCollection 2025.
7
Addressing Knowledge Gaps in the Early Detection of Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: An Official American Thoracic Society Research Statement.解决造血细胞移植后闭塞性细支气管炎综合征早期检测中的知识空白：美国胸科学会官方研究声明
Am J Respir Crit Care Med. 2025 Aug;211(8):1369-1390. doi: 10.1164/rccm.202506-1352ST.
8
Chronic Graft-versus-host Disease, Part 1: How Preclinical Models Shape Our Understanding of Biology and Pave the Way for Future Therapeutic Interventions.慢性移植物抗宿主病，第1部分：临床前模型如何塑造我们对生物学的理解并为未来的治疗干预铺平道路。
Transplantation. 2025 Jun 24. doi: 10.1097/TP.0000000000005444.
9
Optimal GVHD Prophylaxis.最佳移植物抗宿主病预防措施
Adv Exp Med Biol. 2025;1475:77-102. doi: 10.1007/978-3-031-84988-6_5.
10
Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease.芦可替尼作为慢性移植物抗宿主病挽救治疗的长期随访结果
Hematol Transfus Cell Ther. 2025 May 11;47(3):103835. doi: 10.1016/j.htct.2025.103835.
本文引用的文献
1
Upregulation of IFN-Inducible and Damage-Response Pathways in Chronic Graft-versus-Host Disease.慢性移植物抗宿主病中干扰素诱导和损伤反应通路的上调
J Immunol. 2016 Nov 1;197(9):3490-3503. doi: 10.4049/jimmunol.1601054. Epub 2016 Sep 30.
2
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner.治疗性调节性T细胞过继性转移以CXCR5依赖的方式改善已建立的小鼠慢性移植物抗宿主病。
Blood. 2016 Aug 18;128(7):1013-7. doi: 10.1182/blood-2016-05-715896. Epub 2016 Jul 6.
3
Genetic risk factors for sclerotic graft-versus-host disease.硬化型移植物抗宿主病的遗传风险因素。
Blood. 2016 Sep 15;128(11):1516-24. doi: 10.1182/blood-2016-05-715342. Epub 2016 Jun 16.
4
Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease.I型干扰素调节慢性皮肤移植物抗宿主病中的炎症、血管病变和纤维化。
J Immunol. 2016 Jul 1;197(1):42-50. doi: 10.4049/jimmunol.1502190. Epub 2016 May 25.
5
Biomarker Panel for Chronic Graft-Versus-Host Disease.慢性移植物抗宿主病的生物标志物组合
J Clin Oncol. 2016 Aug 1;34(22):2583-90. doi: 10.1200/JCO.2015.65.9615. Epub 2016 May 23.
6
Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study.在血液系统恶性肿瘤患者的清髓性同胞异基因移植中，与非格司亭动员的外周血相比，非格司亭刺激的骨髓：一项加拿大血液和骨髓移植组的随机研究。
Biol Blood Marrow Transplant. 2016 Aug;22(8):1410-1415. doi: 10.1016/j.bbmt.2016.04.017. Epub 2016 May 3.
7
Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.造血干细胞移植后急性白血病患者供者 EBV 血清学状态对移植物抗宿主病发生率的影响：欧洲血液和骨髓移植学会急性白血病和传染病工作组的一项研究。
J Clin Oncol. 2016 Jul 1;34(19):2212-20. doi: 10.1200/JCO.2015.64.2405. Epub 2016 Apr 18.
8
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.慢性移植物抗宿主病生物标志物的异质性：与CXCL10和CXCR3 +自然杀伤细胞的关联
Blood. 2016 Jun 16;127(24):3082-91. doi: 10.1182/blood-2015-09-668251. Epub 2016 Mar 28.
9
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.靶向Rho相关激酶2抑制通过Stat3依赖性机制抑制小鼠和人类慢性移植物抗宿主病。
Blood. 2016 Apr 28;127(17):2144-54. doi: 10.1182/blood-2015-10-678706. Epub 2016 Mar 16.
10
Circulating T follicular helper cells with increased function during chronic graft-versus-host disease.慢性移植物抗宿主病期间功能增强的循环滤泡辅助性T细胞。
Blood. 2016 May 19;127(20):2489-97. doi: 10.1182/blood-2015-12-688895. Epub 2016 Mar 4.
Zotero 插件